Bridgebio Pharma Inc

9.09.2026 г., 22:46 ч. UTC

BridgeBio Pharma Inc shares are higher in after-market trading, despite no specific news. Broader market pressure persists from rising crude oil prices above $100.

2.09.2026 г., 19:36 ч. UTC

BridgeBio Pharma will present new infigratinib data at a pediatric endocrinology meeting in September. HC Wainwright maintains a Buy rating and $120 price target.

1.09.2026 г., 23:16 ч. UTC

BridgeBio Pharma shares are lower in after-market hours following a $500 million mixed securities shelf filing, raising concerns about potential dilution.

28.08.2026 г., 20:08 ч. UTC

BridgeBio Pharma Inc's shares are lower today, continuing a downward trend despite positive social media discussions regarding its treatment, Attruby, based on WF's analysis.

20.08.2026 г., 19:46 ч. UTC

Shares lower amid broader biotechnology sector decline.

19.08.2026 г., 23:01 ч. UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18.08.2026 г., 20:06 ч. UTC

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14.08.2026 г., 20:06 ч. UTC

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13.08.2026 г., 23:01 ч. UTC

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12.08.2026 г., 19:51 ч. UTC

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11.08.2026 г., 22:36 ч. UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10.08.2026 г., 23:21 ч. UTC

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7.08.2026 г., 20:03 ч. UTC

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6.08.2026 г., 19:16 ч. UTC

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5.08.2026 г., 19:16 ч. UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4.08.2026 г., 19:36 ч. UTC

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3.08.2026 г., 20:06 ч. UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31.07.2026 г., 19:56 ч. UTC

BBIO shares decline, continuing a three-day trend amid sector weakness.

30.07.2026 г., 20:21 ч. UTC

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29.07.2026 г., 17:36 ч. UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28.07.2026 г., 19:07 ч. UTC

BBIO shares lower today amid declining biotech sector sentiment.

27.07.2026 г., 18:26 ч. UTC

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.